PMS-METOPROLOL-L TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
24-09-2020
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
METOPROLOL TARTRATE
Beschikbaar vanaf:
PHARMASCIENCE INC
ATC-code:
C07AB02
INN (Algemene Internationale Benaming):
METOPROLOL
Dosering:
50MG
farmaceutische vorm:
TABLET
Samenstelling:
METOPROLOL TARTRATE 50MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100/500/1000
Prescription-type:
Prescription
Therapeutisch gebied:
BETA-ADRENERGIC BLOCKING AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0111923002; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
1997-03-10
Productkenmerken
PRODUCT MONOGRAPH
PR
PMS-METOPROLOL-L
Metoprolol Tartrate Tablets, USP
25 mg, 50 mg and 100 mg
Β-ADRENERGIC RECEPTOR BLOCKING AGENT
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
DATE OF REVISION:
September 24, 2020
www.pharmascience.com
SUBMISSION CONTROL NO: 240530
_pms-METOPROLOL-L Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
DETAILED PHARMACOLOGY
.....................................................................................27
TOXICOLOGY
...............................
Lees het volledige document
